F. Membreno

发表

The HCV NS5B nucleoside and non-nucleoside inhibitors.

E. Lawitz, F. Membreno, 2011, Clinics in liver disease.

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

H. Dvory‐Sobol, D. Brainard, J. McHutchison, 2015, Hepatology.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.

Response‐guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

E. Lawitz, F. Membreno, 2014, Journal of gastroenterology and hepatology.

sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4

D. Brainard, J. McHutchison, E. Lawitz, 2013 .

Cyclophilin inhibitors for hepatitis C therapy.

E. Lawitz, F. Membreno, J. Espinales, 2013, Clinics in liver disease.

Liver transplantation for sinusoidal obstructive syndrome (veno‐occlusive disease): case report with review of the literature and the UNOS database

J. Ortiz, F. Membreno, C. Lemaistre, 2008, Clinical transplantation.

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

J. Chan, D. Rockey, P. Thuluvath, 2020, Journal of hepatology.

Antiviral therapy for treatment-naïve hepatitis B virus patients.

F. Membreno, D. Lau, 2004, Gastroenterology clinics of North America.

Differences in long‐term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed

E. Walser, F. Membreno, D. Lau, 2005, Journal of gastroenterology and hepatology.

The first documented case of fulminant liver failure from herpes simplex virus in an immunocompromised patient taking to facitinib

F. Membreno, J. Beck, H. Haggard, 2020 .

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.